Michael A Carducci1, Judith Manola2, Suresh G Nair3, Glenn Liu4, Steven Rousey5, Janice P Dutcher6, George Wilding7. 1. Johns Hopkins Kimmel Cancer Center, Baltimore, MD. 2. Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA. Electronic address: jmanola@jimmy.harvard.edu. 3. Hematology/Oncology Associates, Lehigh Valley Hospital-Cedar Crest, Allentown, PA. 4. University of Wisconsin Carbone Cancer Center, Wisconsin Institute for Medical Research, Madison, WI. 5. Metro-Minnesota CCOP, Edina, MN. 6. Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY. 7. University of Wisconsin Carbone Cancer Center, Madison, WI.
Abstract
BACKGROUND: Atrasentan, an oral endothelin receptor A antagonist, demonstrated phase 1 activity in patients with renal cell carcinoma (RCC). A phase 2 study was undertaken in patients with measurable or bone-only metastatic RCC in the pre-VEGF/TKI era. METHODS AND MATERIALS: Patients were stratified by disease status and prior immunotherapy. Eligible patients had no prior chemotherapy, 0 to 1 prior immunotherapies, and an Eastern Cooperative Oncology Group performance status of 0 to 2. Patients received atrasentan 10 mg per day until progression. The primary end point was progression-free (PF) rate at 6 months. Rates of 25% among patients treated with prior immunotherapy and 45% among patients with no prior immunotherapy were considered promising. A 2-stage design was used for cohorts without prior immunotherapy. RESULTS: From 2003 to 2005, 98 patients were registered. Median treatment duration was 9.9 weeks (range, 0.3-107 weeks). Toxicities were mild; 71% of patients reported no grade 3 or higher treatment-related events. Grade 4 events included neutropenia (n = 3), dyspnea (n = 2), thrombosis (n = 1), and arrhythmia (n = 1). Two grade 5 events (dyspnea and constitutional) were possibly treatment related. Six-month PF rates (90% confidence interval) were 14% (6-25), 0% (0-39), 8% (1-23), and 22% (8-44), respectively, for patients with prior immunotherapy/measurable disease (n = 44), prior immunotherapy/bone metastases (n = 6), no prior immunotherapy/measurable disease (n = 25), and no prior immunotherapy/bone metastases (n = 18). Median PF survival was 2.3 months (95% confidence interval, 2.0-3.5 months). CONCLUSION: Although well tolerated, atrasentan did not yield 6-month PF rates supporting its use as first-line monotherapy in patients with advanced RCC.
BACKGROUND: Atrasentan, an oral endothelin receptor A antagonist, demonstrated phase 1 activity in patients with renal cell carcinoma (RCC). A phase 2 study was undertaken in patients with measurable or bone-only metastatic RCC in the pre-VEGF/TKI era. METHODS AND MATERIALS: Patients were stratified by disease status and prior immunotherapy. Eligible patients had no prior chemotherapy, 0 to 1 prior immunotherapies, and an Eastern Cooperative Oncology Group performance status of 0 to 2. Patients received atrasentan 10 mg per day until progression. The primary end point was progression-free (PF) rate at 6 months. Rates of 25% among patients treated with prior immunotherapy and 45% among patients with no prior immunotherapy were considered promising. A 2-stage design was used for cohorts without prior immunotherapy. RESULTS: From 2003 to 2005, 98 patients were registered. Median treatment duration was 9.9 weeks (range, 0.3-107 weeks). Toxicities were mild; 71% of patients reported no grade 3 or higher treatment-related events. Grade 4 events included neutropenia (n = 3), dyspnea (n = 2), thrombosis (n = 1), and arrhythmia (n = 1). Two grade 5 events (dyspnea and constitutional) were possibly treatment related. Six-month PF rates (90% confidence interval) were 14% (6-25), 0% (0-39), 8% (1-23), and 22% (8-44), respectively, for patients with prior immunotherapy/measurable disease (n = 44), prior immunotherapy/bone metastases (n = 6), no prior immunotherapy/measurable disease (n = 25), and no prior immunotherapy/bone metastases (n = 18). Median PF survival was 2.3 months (95% confidence interval, 2.0-3.5 months). CONCLUSION: Although well tolerated, atrasentan did not yield 6-month PF rates supporting its use as first-line monotherapy in patients with advanced RCC.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Michael A Carducci; Joel B Nelson; M Kathy Bowling; Theresa Rogers; Mario A Eisenberger; Victoria Sinibaldi; Ross Donehower; Terri L Leahy; Robert A Carr; Jeffrey D Isaacson; Todd J Janus; Amy Andre; Balakrishna S Hosmane; Robert J Padley Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: Michael A Carducci; Robert J Padley; Jurgen Breul; Nicholas J Vogelzang; Bernard A Zonnenberg; Danai D Daliani; Claude C Schulman; Azmi A Nabulsi; Rod A Humerickhouse; Mark A Weinberg; Jennifer L Schmitt; Joel B Nelson Journal: J Clin Oncol Date: 2003-02-15 Impact factor: 44.544
Authors: Bernard A Zonnenberg; Gerard Groenewegen; Todd J Janus; Terri W Leahy; Rod A Humerickhouse; Jeffrey D Isaacson; Robert A Carr; Emile Voest Journal: Clin Cancer Res Date: 2003-08-01 Impact factor: 12.531
Authors: Laura Rosanò; Francesca Spinella; Debora Salani; Valeriana Di Castro; Aldo Venuti; Maria Rita Nicotra; Pier Giorgio Natali; Anna Bagnato Journal: Cancer Res Date: 2003-05-15 Impact factor: 12.701
Authors: Robert J Motzer; Jennifer Bacik; Lawrence H Schwartz; Victor Reuter; Paul Russo; Stephanie Marion; Madhu Mazumdar Journal: J Clin Oncol Date: 2004-02-01 Impact factor: 44.544
Authors: J B Nelson; S P Hedican; D J George; A H Reddi; S Piantadosi; M A Eisenberger; J W Simons Journal: Nat Med Date: 1995-09 Impact factor: 53.440
Authors: Brianna Marie Lutz; Shaogen Wu; Xiyao Gu; Fidelis E Atianjoh; Zhen Li; Brandon M Fox; David M Pollock; Yuan-Xiang Tao Journal: Haematologica Date: 2018-03-15 Impact factor: 9.941